Clinical Trial Update: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 trial evaluating five years of adjuvant osimertinib in completely resected EGFR-mutant non-small cell lung cancer (stages II–IIIB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Stage II-IIIB Non-small Cell Lung Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING